124 related articles for article (PubMed ID: 2938955)
1. Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
Bonte J; Janssens JP; Ide P
Eur J Gynaecol Oncol; 1986; 7(1):45-50. PubMed ID: 2938955
[TBL] [Abstract][Full Text] [Related]
2. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
[TBL] [Abstract][Full Text] [Related]
3. Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.
Noguchi S; Yamamoto H; Inaji H; Imaoka S; Koyama H
Jpn J Cancer Res; 1989 Mar; 80(3):244-8. PubMed ID: 2524460
[TBL] [Abstract][Full Text] [Related]
4. New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies.
Vanderstappen D; Bonte J
Eur J Gynaecol Oncol; 1992; 13(2):113-23. PubMed ID: 1534051
[TBL] [Abstract][Full Text] [Related]
5. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
Thurzó L
Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
[TBL] [Abstract][Full Text] [Related]
6. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study.
De Lena M; Tommasi S; Schittulli F; Lorusso V; Paradiso A
Tumori; 1990 Apr; 76(2):190-5. PubMed ID: 2139523
[TBL] [Abstract][Full Text] [Related]
7. Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a-anthracene-induced rat mammary tumors in relation to hormone receptors.
Tominaga T; Yoshida Y; Kitamura M; Kosaki G
Jpn J Cancer Res; 1985 Nov; 76(11):1120-5. PubMed ID: 2935517
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
9. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
Kline RC; Freedman RS; Jones LA; Atkinson EN
Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831
[No Abstract] [Full Text] [Related]
10. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
Mauriac L; Durand M; Bonichon F; Chauvergne J
Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
[TBL] [Abstract][Full Text] [Related]
11. Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma.
Riippa P; Kauppila A; Sundström H; Vihko R
Anticancer Res; 1984; 4(3):109-12. PubMed ID: 6235770
[TBL] [Abstract][Full Text] [Related]
12. Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma.
Satyaswaroop PG; Zaino R; Clarke CL; Mortel R
J Steroid Biochem; 1987; 27(1-3):431-8. PubMed ID: 2961935
[TBL] [Abstract][Full Text] [Related]
13. [Hormones in gynecologic oncology].
Maass H
Arch Gynecol Obstet; 1989; 245(1-4):466-73. PubMed ID: 2802734
[No Abstract] [Full Text] [Related]
14. The endometrial adenocarcinoma as a model for hormone-dependency and hormone-responsiveness of gynaecological cancers.
Bonte J
Eur J Obstet Gynecol Reprod Biol; 1984 Dec; 18(5-6):335-41. PubMed ID: 6526120
[TBL] [Abstract][Full Text] [Related]
15. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Noguchi S; Yamamoto H; Inaii H; Koyama H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
[TBL] [Abstract][Full Text] [Related]
16. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
17. Effects of tamoxifen, estradiol benzoate and medroxyprogesterone acetate on the growth of DMBA-induced rat mammary carcinoma.
Zanardi S; De Menech R; Pino G; Guarneri D; Dandolo G; Sanguineti M; Moro MG; Barbi GP; Paganuzzi M; Boccardo F
Chemioterapia; 1985 Jun; 4(3):239-42. PubMed ID: 3161642
[TBL] [Abstract][Full Text] [Related]
18. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
19. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
[TBL] [Abstract][Full Text] [Related]
20. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
